Plain-English translation of NCT06617793 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called YTB323 for people with relapsing multiple sclerosis who are still experiencing disease activity even though they're already on a strong disease-fighting treatment. The study will give you one dose of this medication and then closely monitor you for safety and how well it works. You'll be followed for 2 years in the main study, plus an additional 13 years in a long-term follow-up to make sure the treatment remains safe over time.
Some people with relapsing multiple sclerosis continue to have disease activity — new symptoms or brain/spinal cord changes — even while taking the strongest available treatments. This trial is exploring whether this new medication could help people whose disease is 'breaking through' their current therapy.
You will receive one dose of the study medication. Depending on safety results in earlier groups, later groups may receive a higher dose. You'll visit the study center for evaluations, blood tests, and brain imaging scans to check for safety and how the medication is working. The main study lasts 2 years, after which you'll be invited to join a long-term follow-up study for an additional 13 years to ensure the treatment remains safe and to track your long-term health.
AI-generated summary from trial data · Aug 15, 2026 · Not medical advice
Australia
France